Products/Services Used | Details | Operation |
---|---|---|
Bacterial Expression> | … Vaccine constructs were designed in-house and produced in E. coli by Genscript … stimulant as a negative control in the presence of Golgi stop (BD biosciences) and a fluorochrome coupled anti-CD107α for 6 h. After washing, cells were stained for cell surface antigens … | Get A Quote |
Combining different immunotherapy approaches is currently building the future of immunotherapy, with the view to maximize anti-tumoral efficacy for larger patient population. The KISIMA™ platform allows the development of protein-based cancer vaccines able to induce tumor-specific T cell response resulting in anti-tumoral efficacy in various mouse models. Intra-tumoral administration of stimulator of interferon gene agonists (STINGa) was shown to induce a potent inflammatory response leading to the development of tumor-specific immunity. Here, we explored the efficacy and mechanisms of action of subcutaneous STINGa treatment combined with therapeutic vaccination in various mouse tumor models. This combinatory... More